Peptides DB
Research-centric peptide and protocol reference hub
Study 26 of 57Semaglutide literatureJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · Observational2026

Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.

In patients with endometrial cancer, sleeve gastrectomy leads to greater short-term weight loss, but a structured lifestyle program may be more effective for long-term weight maintenance and metabolic health.

Read at Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and GynaecologyAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
13
Preclinical
34
Observational · this one
2
Open-label
2
Randomised
6
Reviews

Summary and findings

This study compared sleeve gastrectomy, semaglutide therapy, and the DEAR weight management program in 53 patients with endometrial cancer. The primary outcome was weight loss and metabolic improvement over two years. Results indicated that sleeve gastrectomy led to the largest BMI reduction at one year, while the DEAR program showed better weight maintenance and metabolic stability at two years.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
sleeve gastrectomy group had a BMI reduction difference of 4.04 kg/m² compared to the semaglutide group, p < 0.052026

Abstract

The authors’ words, as Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology supplied them

<h4>Background</h4>To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.<h4>Methods</h4>In this prospective observational study, 53 patients received sleeve gastrectomy (<i>n</i> = 10), semaglutide therapy (<i>n</i> = 23), or the DEAR programme (<i>n</i> = 20) after multidisciplinary assessment and shared decision-making. Anthropometric and metabolic measures and tumour response were assessed over two years.<h4>Results</h4>At 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m<sup>2</sup>, <i>p</i> < 0.05) and the DEAR group (difference = 2.12 kg/m<sup>2</sup>, <i>p</i> < 0.05). By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (<i>p</i> = 0.037). The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).<h4>Conclusion</h4>Sleeve gastrectomy produced rapid short-term weight loss, whereas the DEAR programme showed better medium-term weight maintenance, metabolic stability, and tumour response. Integrated lifestyle support may be a useful medium-term strategy for patients seeking fertility preservation.

Elsewhere in the Semaglutide corpus

DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.reviewBWeight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort studybiorxiv-preprint · At 16 weeks, NMGP users lost 8.3% of their baseline weight.HumanBSide effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studybiorxiv-preprint · 34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.HumanBA study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis.Renal failure · 2026 · n=875 · AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).HumanBFeasibility and acceptability of an everyday patient-centered discussion model for primary care: An exploratory, single-center study in the VA primary care setting.PEC innovation · 2026 · n=23 · Mean SDM-Q-9 score was 90.9 out of 100.HumanBOral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventionsbiorxiv-preprint · 2026 · 8.69% of GLP-1 users developed at least one newly documented oral-health condition.Human